News | June 29, 2022
Glenmark Pharmaceuticals expand its OTC portfolio
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Glenmark is the first company in India to market the innovative FDC of Indacaterol
A total of five observations for Goa and 17 for Monroe
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated
